Forodesine
As of the edition of 20 October 2026, Forodesine is a small molecule: marketed, first approved in 2017 (JP); acts on PNP.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Mundesine
- First approved
- 30 March 2017 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Mundi Pharma; 2 holders in all
- Registered trials
- 14, 3 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Infections; Digestive system; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PNP | Purine nucleoside phosphorylase | P00491 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 3 | 0 | 1 |
| Phase 2 | 10 | 8 | 0 | 2 |
| All trials | 14 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Mundipharma | Applicant and Lead sponsor of trials | 2009 to now |